相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Stacie B. Dusetzina et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The Slowdown In Health Care Spending In 2009-11 Reflected Factors Other Than The Weak Economy And Thus May Persist
Alexander J. Ryu et al.
HEALTH AFFAIRS (2013)
Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists
Rena M. Conti et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Out of Pocket, Out of Sight? An Unmeasured Component of the Burden of Cancer
Matthew P. Banegas et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Growth In US Health Spending Remained Slow In 2010; Health Share Of Gross Domestic Product Was Unchanged From 2009
Anne B. Martin et al.
HEALTH AFFAIRS (2012)
Phase 2 Study of Nilotinib as Third-Line Therapy for Patients With Gastrointestinal Stromal Tumor
Akira Sawaki et al.
CANCER (2011)
Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial.
H. L. Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Projections of the Cost of Cancer Care in the United States: 2010-2020
Angela B. Mariotto et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis
D. Cella et al.
BRITISH JOURNAL OF CANCER (2010)
How Medicare's Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment
Mireille Jacobson et al.
HEALTH AFFAIRS (2010)
Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
Thomas E. Hutson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
An economic evaluation of the war on cancer
Darius N. Lakdawalla et al.
JOURNAL OF HEALTH ECONOMICS (2010)
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
D. Castellano et al.
ANNALS OF ONCOLOGY (2009)
A Phase 2 Study With a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients With Metastatic Clear Cell Renal Cell Cancer
Robert J. Amato et al.
CANCER (2009)
Prescription Drug Spending Trends In The United States: Looking Beyond The Turning Point
Murray Aitken et al.
HEALTH AFFAIRS (2009)
Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
Jane F. Apperley et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Peter B. Bach
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M. Kantarjian et al.
BLOOD (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia:: Results of a prospective phase II open-label multicenter study
G Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
